PACB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Pacific Biosciences of California Inc (PACB) is not a strong buy at this moment for a beginner investor with a long-term strategy. The stock lacks strong positive catalysts, has weak financial performance, and no significant trading signals. While there is some improvement in gross margin and upcoming earnings could provide clarity, the overall sentiment and technical indicators suggest a cautious approach.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 33.06, and moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 1.726), but with no strong upward momentum.
Upcoming Q4 earnings report with expected EPS improvement of 35% YoY and revenue growth of 9.2% YoY. Gross margin increased significantly in the last quarter, up 219.75% YoY.
Declining revenue (-3.82% YoY), net income (-37.42% YoY), and EPS (-40.91% YoY) in the last quarter. Analysts' price target increase is modest, and trading trends are neutral with no significant insider or hedge fund activity. Stock trend analysis suggests a potential decline in the next week (-2.5%) and month (-9.8%).
In Q3 2025, revenue dropped to $38.44M (-3.82% YoY), net income fell to -$38M (-37.42% YoY), and EPS declined to -$0.13 (-40.91% YoY). However, gross margin improved significantly to 50.84% (+219.75% YoY).
Barclays raised the price target from $1.50 to $2 with an Equal Weight rating. Analysts see potential in the tools group for 2026 but remain cautious on PACB in the near term.
